Silvia Gomez de Castiglia
Silvia Gomez de Castiglia publishes mostly in Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology, on topics such as Radiopharmaceutical Chemistry and Applications, Monoclonal and Polyclonal Antibodies Research and Medical Imaging and Pathology Studies.
- World rank
- #6,349,904 of 7,710,434 ranked researchers
- Rank in Argentina
- #25,752 of 38,473
- Works
- 30
- Citations
- 231
- Citations per work
- 7.7
What does Silvia Gomez de Castiglia research?
Silvia Gomez de Castiglia's work is mostly in Medicine (70%), Biochemistry, Genetics and Molecular Biology (6%), Pharmacology, Toxicology and Pharmaceutics (2%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences2169.8%
- Medicine2169.8%
- Everything else721.8%
- Life Sciences38.4%
- 1Radiology, Nuclear Medicine and Imaging41% of their works
- 2Pulmonary and Respiratory Medicine12% of their works
- 3Oncology12% of their works
- 4Molecular Biology6% of their works
- 5Epidemiology5% of their works
- 6Pharmaceutical Science2% of their works
Research topics
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging and Pathology Studies
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Medical Imaging Techniques and Applications
- Biotin and Related Studies
- Protein purification and stability
Which keywords describe Silvia Gomez de Castiglia's research?
The keywords of their largest research topics: PET Imaging, Radiopharmaceuticals, Targeted Therapy, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors and Pulmonary Alveolar Microlithiasis.
- Protein Aggregation
- Biopharmaceuticals
- Pancreatic Neuroendocrine Tumors
- Neuroendocrine Tumors
- Fibroblast Activation Protein
- Pulmonary Alveolar Microlithiasis
- Antibody Engineering
- Monoclonal Antibodies
- Radiopharmaceuticals
- PET Imaging
- Targeted Therapy
- Therapeutic Antibodies
- Fc Receptors
- Pulmonary Sclerosing Hemangioma
- Imaging
- PET/CT
- Tumor Microenvironment
- Biotin
- Proximity Labeling
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- PET Imaging262 topics
- Radiopharmaceuticals221 topic
- Targeted Therapy221 topic
- Monoclonal Antibodies102 topics
- Therapeutic Antibodies102 topics
- Antibody Engineering81 topic
- Fc Receptors81 topic
- Pulmonary Alveolar Microlithiasis61 topic
- Pulmonary Sclerosing Hemangioma61 topic
- Fibroblast Activation Protein41 topic
- Imaging41 topic
- Neuroendocrine Tumors41 topic
- PET/CT41 topic
- Pancreatic Neuroendocrine Tumors41 topic
- Tumor Microenvironment41 topic
- Biopharmaceuticals21 topic
- Biotin21 topic
- Protein Aggregation21 topic
- Proximity Labeling21 topic
Where does Silvia Gomez de Castiglia work?
Silvia Gomez de Castiglia's main affiliation in the publication record is Comisión Nacional de Energía Atómica, Argentina.
How many publications and citations does Silvia Gomez de Castiglia have?
OpenAlex counts 30 works and 231 citations for Silvia Gomez de Castiglia, an h-index of 5, ranking #6,349,904 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Silvia Gomez de Castiglia. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.